Patents Assigned to Edison Pharmaceuticals, Inc.
  • Identifying therapeutic compounds based on their physical-chemical properties
    Patent number: 7491312
    Abstract: The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: February 17, 2009
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Sylvain Gilat, Gary Binyamin, Guy Miller
  • 7,8-bicycloalkyl-chroman derivatives
    Patent number: 7470798
    Abstract: 7,8-Bicyclic-chroman derivatives of Formula I: wherein the substituents are defined as in the specification or the pharmaceutically acceptable salts thereof, are disclosed. They are useful for the treatment of inflammatory disorders, neurodegenerative disorders and/or mitochondrial disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: December 30, 2008
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Bing Wang, Gail Walkinshaw, Jian Chen, Xianming Jin, Jiangao Song, Wei Zhang
  • Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
    Patent number: 7432305
    Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: October 7, 2008
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Guy M. Miller, Sidney M. Hecht